AR082152A1 - Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7 - Google Patents
Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7Info
- Publication number
- AR082152A1 AR082152A1 ARP110102489A ARP110102489A AR082152A1 AR 082152 A1 AR082152 A1 AR 082152A1 AR P110102489 A ARP110102489 A AR P110102489A AR P110102489 A ARP110102489 A AR P110102489A AR 082152 A1 AR082152 A1 AR 082152A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- independently
- cycloalkyl
- alkyl
- het1
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 2
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 title 1
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 229940124777 Nav1.7 inhibitor Drugs 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 150000003456 sulfonamides Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Derivados de sulfonamida, su uso en medicina, composiciones que los contienen. Los inhibidores de Nav1.7. se utilizan en el tratamiento de un amplio rango de trastornos, en particular, del dolor.Reivindicación 1: Un compuesto caracterizado por la fórmula (1) o una sal de este farmacéuticamente aceptable, en donde X es O, S, NH o CH2; Ar1 es (i) naftilo; o (ii) naftilo o fenilo, cada uno de los cuales se sustituye, independientemente, con 1 a 3 Y; Y es F; Cl; CN; alquilo C1-8, opcionalmente sustituido con cicloalquilo C3-8 y/o, si lo permite la valencia, con 1 a 8 F; cicloalquilo C3-8, opcionalmente sustituido, si lo permite la valencia, con 1 a 8 F; NR7R8, alquiloxi C1-8, opcionalmente sustituido, de forma independiente, con 1 a 3 R9, o si lo permite la valencia, con 1 a 8 F; cicloalquiloxi C3-8; fenilo, opcionalmente sustituido, en forma independiente, con 1 a 3 R10; Het1 y Het2; en donde cicloalquiloxi C3-8 puede fusionarse opcionalmente a un anillo de fenilo o puede sustituirse, en forma independiente, con 1 a 3 R10; R1 es alquilo C1-6 o cicloalquilo C3-8, cada uno de los cuales se sustituye opcionalmente, si lo permite la valencia, con 1 a 8 F; R2, R3, R4 son, independientemente, H, F, Cl u -OCH3; R5 es H, CN, F, Cl o R6; R6 es un grupo seleccionado de alquilo C1-6 y alquiloxi C1-6, en donde cada grupo se sustituye, opcionalmente, si lo permite la valencia, con 1 a 8 F; R7 y R8 son, independientemente, H; alquilo C1-8, opcionalmente sustituido, en forma independiente, con 1 a 3 R11; cicloalquilo C3-8; o Het1 “unido a C”; en donde cicloalquilo C3-8 puede fusionarse opcionalmente a un anillo de fenilo o puede sustituirse, en forma independiente, con 1 a 3 R10; o R7 y R8, junto con el átomo de nitrógeno al que están unidos, forman un anillo de 7 a 9 miembros en puente, saturado; R9 es alquiloxi C1-6; cicloalquilo C3-8, opcionalmente sustituido, si lo permite la valencia, con 1 a 8 F; Het1 o fenilo, opcionalmente sustituido, en forma independiente, con 1 a 3 R6; R10 es F, Cl o R6; R11 es F; alquiloxi C1-6; cicloalquilo C3-8, opcionalmente sustituido, silo permite la valencia, con 1 a 8 F; Het1 “unido a C”; o fenilo, opcionalmente sustituido, en forma independiente, con 1 a 3 R6; Het1 es un monoheterocicloalquilo saturado de 3 a 8 miembros que comprende 1 ó 2 miembros del anillo seleccionados de -NR12- y -O-, en donde dicho monoheterocicloalquilo se sustituye, opcionalmente, en un átomo de carbono del anillo con 1 a 3 sustituyentes seleccionados, independientemente, de F, alquilo C1-6, alquiloxi C1-4-alquileno C0-4 y cicloalquilo C3-8; Het2 es un heteroarilo de 5 ó 6 miembros que comprende de 1 a 3 átomos de nitrógeno, en donde dicho heteroarilo se sustituye, opcionalmente, con 1 a 3 sustituyentes seleccionados de F, Cl, CN y R6; y R12 es H, alquilo C1-6 o cicloalquilo C3-8, en donde alquilo C1-6 y cicloalquilo C3-8 se sustituye, opcionalmente, si lo permite la valencia, con 1 a 8 F; o, cuando Het1 está “unido a N”, está ausente.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36335510P | 2010-07-12 | 2010-07-12 | |
| US201161473287P | 2011-04-08 | 2011-04-08 | |
| US201161488972P | 2011-05-23 | 2011-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082152A1 true AR082152A1 (es) | 2012-11-14 |
Family
ID=45439021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102489A AR082152A1 (es) | 2010-07-12 | 2011-07-11 | Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8685977B2 (es) |
| EP (1) | EP2593427B1 (es) |
| JP (1) | JP2013536165A (es) |
| AR (1) | AR082152A1 (es) |
| CA (1) | CA2804877A1 (es) |
| ES (1) | ES2532357T3 (es) |
| TW (1) | TW201216956A (es) |
| UY (1) | UY33500A (es) |
| WO (1) | WO2012007883A1 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5872552B2 (ja) | 2010-07-09 | 2016-03-01 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化学化合物 |
| ES2526675T3 (es) | 2010-07-09 | 2015-01-14 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
| CA2804593C (en) | 2010-07-09 | 2015-11-24 | Pfizer Limited | Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors |
| JP2013532184A (ja) * | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体 |
| JP2013532185A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 化合物 |
| CA2804351A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| JP2013531030A (ja) | 2010-07-12 | 2013-08-01 | ファイザー・リミテッド | 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド |
| US9630929B2 (en) | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| US20150291514A1 (en) * | 2012-01-04 | 2015-10-15 | Pfizer Limted | N-Aminosulfonyl Benzamides |
| SG11201408284VA (en) | 2012-05-22 | 2015-02-27 | Xenon Pharmaceuticals Inc | N-substituted benzamides and their use in the treatment of pain |
| US10071957B2 (en) | 2012-07-06 | 2018-09-11 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
| US9388179B2 (en) | 2012-10-26 | 2016-07-12 | Merck Sharp & Dohme Corp. | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels |
| US9550775B2 (en) | 2013-03-14 | 2017-01-24 | Genentech, Inc. | Substituted triazolopyridines and methods of use thereof |
| MX2015010775A (es) | 2013-03-15 | 2016-04-25 | Genentech Inc | Benzoxazoles sustituidos y metodos para usarlos. |
| ES2687481T3 (es) * | 2013-03-15 | 2018-10-25 | Chromocell Corporation | Moduladores del canal de sodio para el tratamiento del dolor |
| AU2014318979B2 (en) | 2013-09-10 | 2019-03-28 | Chromocell Corporation | Sodium channel modulators for the treatment of pain and diabetes |
| CR20160296A (es) | 2013-11-27 | 2016-09-20 | Genentech Inc | Benzamidas sustituidas y métodos para usarlas |
| CN106715418A (zh) | 2014-07-07 | 2017-05-24 | 基因泰克公司 | 治疗化合物及其使用方法 |
| US10278942B2 (en) * | 2015-03-11 | 2019-05-07 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
| JP2018520107A (ja) | 2015-05-22 | 2018-07-26 | ジェネンテック， インコーポレイテッド | 置換ベンズアミド及びその使用方法 |
| EP3341353A1 (en) | 2015-08-27 | 2018-07-04 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| CN108290881B (zh) | 2015-09-28 | 2021-12-07 | 健泰科生物技术公司 | 治疗性化合物和其使用方法 |
| US10899732B2 (en) | 2015-11-25 | 2021-01-26 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| US20170239183A1 (en) * | 2016-02-23 | 2017-08-24 | PixarBio Corporation | COMPOSITIONS COMPRISING NAv1.7 SELECTIVE INHIBITORS FOR TREATING ACUTE, POST-OPERATIVE, OR CHRONIC PAIN AND METHODS OF USING THE SAME |
| EP3854782A1 (en) | 2016-03-30 | 2021-07-28 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| AU2017347549A1 (en) | 2016-10-17 | 2019-05-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| JP2020511511A (ja) | 2017-03-24 | 2020-04-16 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体 |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| WO2019191702A1 (en) | 2018-03-30 | 2019-10-03 | F. Hoffmann-La Roche Ag | Substituted hydro-pyrido-azines as sodium channel inhibitors |
| WO2019200369A1 (en) * | 2018-04-13 | 2019-10-17 | Chromocell Corporation | Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| WO2021119157A1 (en) | 2019-12-11 | 2021-06-17 | Duke University | Small molecule inhibitors of voltage-gated sodium channel 1.7 and methods of using same |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2960664D1 (en) | 1978-01-19 | 1981-11-19 | Ici Plc | Diphenyl ether compounds useful as herbicides; methods of using them, processes for preparing them, and herbicidal compositions containing them |
| DE3061064D1 (en) | 1979-07-18 | 1982-12-16 | Ici Plc | Herbicidal compositions comprising a diphenyl ether compound in admixture with another herbicide |
| GR71915B (es) | 1979-11-27 | 1983-08-16 | Pfizer | |
| US4744818A (en) | 1981-07-27 | 1988-05-17 | Rhone-Poulenc Agrochimie | Herbicidal N-halo-5(substituted-phenoxy or -pyridyloxy)-2-substituted benzoic acid sulfonamides and sulfamates |
| EP0194599A3 (en) | 1985-03-14 | 1988-01-20 | Nissan Chemical Industries Ltd. | Benzamide derivatives, process for producing the same, and soil fungicides containing the same |
| HUT48799A (en) | 1986-08-20 | 1989-07-28 | Fmc Corp | Herbicides containing as active substance derivatives of triazolinon and process for production of the active substances |
| US5084085A (en) * | 1986-08-20 | 1992-01-28 | Fmc Corporation | Herbicidal aryloxyphenyltriazolinones and related compounds |
| US4845264A (en) | 1987-03-05 | 1989-07-04 | Teijin Limited | Phenoxycarboxylic acid and herbicide comprising it as active ingredient |
| US4920132A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US4920133A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US4920130A (en) | 1987-11-02 | 1990-04-24 | Rorer Pharamceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US4920131A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| DE68909958D1 (de) | 1988-01-19 | 1993-11-25 | Tanabe Seiyaku Co | Phenoxyessigsäure-Derivate, ihre Herstellung, pharmazeutische Zusammensetzungen, die sie enthalten, und deren Verwendung. |
| GB8911854D0 (en) | 1989-05-23 | 1989-07-12 | Ici Plc | Heterocyclic compounds |
| EP0412848B1 (en) | 1989-08-11 | 1995-01-18 | Zeneca Limited | Quinoline derivatives, process for their preparation and their use as medicaments |
| US4945113A (en) | 1989-09-29 | 1990-07-31 | Uniroyal Chemical Company, Inc. | herbicidal sulfonamide derivatives |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB2244054B (en) | 1990-04-19 | 1994-04-06 | Ici Plc | Pyridine derivatives |
| WO1993000332A1 (en) | 1991-06-25 | 1993-01-07 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| GB2266527A (en) | 1992-03-17 | 1993-11-03 | Merck & Co Inc | Substituted azetidinones useful in the treatment of leukemia |
| JPH05289262A (ja) | 1992-04-10 | 1993-11-05 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| JPH05307242A (ja) | 1992-04-28 | 1993-11-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| JP3101848B2 (ja) | 1992-05-15 | 2000-10-23 | 富士写真フイルム株式会社 | ハロゲン化銀カラー写真感光材料 |
| FR2694295B1 (fr) | 1992-07-28 | 1994-09-02 | Adir | Nouveaux peptides dérivés de trifluoromethylcetones, leur procéde de préparation et les compositions pharmaceutiques qui les contiennent. |
| AU5802894A (en) | 1992-12-17 | 1994-07-04 | Merck & Co., Inc. | New substituted azetidinones as anti-inflammatory and antidegenerative agents |
| PT617001E (pt) | 1993-03-19 | 2000-06-30 | Merck & Co Inc | Derivados do acido fenoxifenilacetico |
| WO1996004905A1 (en) | 1994-08-08 | 1996-02-22 | Merck & Co., Inc. | Phenoxyphenylacetic acid derivatives |
| JPH06347968A (ja) | 1993-04-14 | 1994-12-22 | Fuji Photo Film Co Ltd | ハロゲン化銀感光材料 |
| JP3503839B2 (ja) | 1994-05-25 | 2004-03-08 | 富士写真フイルム株式会社 | ポジ型感光性組成物 |
| WO1996009818A1 (en) | 1994-09-27 | 1996-04-04 | Merck & Co., Inc. | Endothelin receptor antagonists for the treatment of emesis |
| GB9514031D0 (en) | 1995-07-10 | 1995-09-06 | Zeneca Ltd | Chemical process |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| JP3519218B2 (ja) | 1996-08-14 | 2004-04-12 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料および画像形成方法 |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| AU745081B2 (en) | 1997-06-27 | 2002-03-14 | Fujisawa Pharmaceutical Co., Ltd. | Sulfonamide compounds and medicinal use thereof |
| US6555584B1 (en) | 2000-06-29 | 2003-04-29 | Ajinomoto Co., Inc. | Acylsulfonamide derivative |
| DE19742951A1 (de) | 1997-09-29 | 1999-04-15 | Hoechst Schering Agrevo Gmbh | Acylsulfamoylbenzoesäureamide, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung |
| AU9696198A (en) | 1997-10-17 | 1999-05-10 | Aventis Pharmaceuticals Products Inc. | Therapeutic uses of quinoline derivatives |
| GB9805520D0 (en) | 1998-03-17 | 1998-05-13 | Zeneca Ltd | Chemical compounds |
| GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
| PL351470A1 (en) | 1999-04-28 | 2003-04-22 | Aventis Pharma Gmbh | Tri-aryl acid derivatives as ppar receptor ligands |
| CA2372079A1 (en) | 1999-05-05 | 2000-11-09 | Aaron H. Leeman | Novel catechols as antimicrobial agents |
| JP2001075213A (ja) | 1999-09-07 | 2001-03-23 | Fuji Photo Film Co Ltd | ハロゲン化銀写真乳剤、その製造方法及びこれを用いたハロゲン化銀写真感光材料 |
| GB9927056D0 (en) | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| IL151517A0 (en) | 2000-03-09 | 2003-04-10 | Aventis Pharma Gmbh | Therapeutic uses of ppar mediators |
| AR031130A1 (es) | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| RO123430B1 (ro) | 2001-11-16 | 2012-04-30 | Toyama Chemical Co., Ltd. | Derivaţi noi de benzofenonă sau sărurile acestora |
| AU2003262805A1 (en) | 2002-08-26 | 2004-03-11 | Merck & Co., Inc. | Acetophenone potentiators of metabotropic glutamate receptors |
| EP1673357A2 (en) | 2003-08-08 | 2006-06-28 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| CA2551909C (en) | 2004-02-12 | 2011-10-11 | Transtech Pharma, Inc. | Substituted azole derivatives, compositions, and methods of use |
| GB0405033D0 (en) | 2004-03-05 | 2004-04-07 | Karobio Ab | Novel pharmaceutical compositions |
| US20080312286A1 (en) | 2004-07-30 | 2008-12-18 | Pinkerton Anthony B | Indanone Potentiators of Metabotropic Glutamate Receptors |
| ZA200703912B (en) * | 2004-10-20 | 2008-09-25 | Serono Lab | 3-arylamino pyridine derivatives |
| JP2008189549A (ja) | 2005-05-12 | 2008-08-21 | Astellas Pharma Inc | カルボン酸誘導体またはその塩 |
| JP2009057282A (ja) | 2005-12-19 | 2009-03-19 | Astellas Pharma Inc | カルボン酸誘導体又はその塩 |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| DE602007011793D1 (de) | 2006-10-18 | 2011-02-17 | Pfizer Prod Inc | Biaryl-ether-harnstoffverbindungen |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| EP1995241B1 (en) | 2007-03-23 | 2010-03-17 | ICAgen, Inc. | Inhibitors of ion channels |
| CA2684105C (en) | 2007-05-03 | 2011-09-06 | Pfizer Limited | Pyridine derivatives |
| US20100179137A1 (en) | 2007-06-07 | 2010-07-15 | Takashi Kamikubo | Pyridone compound |
| US8124610B2 (en) | 2007-07-13 | 2012-02-28 | Icagen Inc. | Sodium channel inhibitors |
| WO2009049181A1 (en) | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Amides useful as inhibitors of voltage-gated sodium channels |
| TW200930368A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| US20090291921A1 (en) | 2007-11-20 | 2009-11-26 | Gilead Sciences, Inc. | Integrase inhibitors |
| JP2011504505A (ja) * | 2007-11-21 | 2011-02-10 | デコード ジェネティクス イーエイチエフ | 肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤 |
| GB0725214D0 (en) | 2007-12-24 | 2008-02-06 | Karobio Ab | Pharmaceutical compounds |
| JP5304785B2 (ja) | 2008-06-23 | 2013-10-02 | アステラス製薬株式会社 | スルホンアミド化合物又はその塩 |
| US8107894B2 (en) | 2008-08-12 | 2012-01-31 | Raytheon Company | Modular solid-state millimeter wave (MMW) RF power source |
| PE20120008A1 (es) | 2009-01-12 | 2012-01-24 | Icagen Inc | Derivados de fenoxi bencenosulfonamida |
| JP5289262B2 (ja) | 2009-09-30 | 2013-09-11 | 京セラドキュメントソリューションズ株式会社 | シート搬送装置とこれを備えた画像読取装置及び画像形成装置 |
| JP5872552B2 (ja) | 2010-07-09 | 2016-03-01 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化学化合物 |
| ES2526675T3 (es) | 2010-07-09 | 2015-01-14 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
| CA2804593C (en) | 2010-07-09 | 2015-11-24 | Pfizer Limited | Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors |
| JP2013532185A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 化合物 |
| JP2013532184A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体 |
| JP2013531030A (ja) | 2010-07-12 | 2013-08-01 | ファイザー・リミテッド | 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド |
| CA2804351A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
-
2011
- 2011-07-07 JP JP2013519195A patent/JP2013536165A/ja not_active Withdrawn
- 2011-07-07 CA CA2804877A patent/CA2804877A1/en not_active Abandoned
- 2011-07-07 EP EP11748997.1A patent/EP2593427B1/en not_active Not-in-force
- 2011-07-07 WO PCT/IB2011/053030 patent/WO2012007883A1/en not_active Ceased
- 2011-07-07 ES ES11748997.1T patent/ES2532357T3/es active Active
- 2011-07-11 UY UY0001033500A patent/UY33500A/es not_active Application Discontinuation
- 2011-07-11 US US13/179,585 patent/US8685977B2/en not_active Expired - Fee Related
- 2011-07-11 AR ARP110102489A patent/AR082152A1/es not_active Application Discontinuation
- 2011-07-11 TW TW100124486A patent/TW201216956A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20120010207A1 (en) | 2012-01-12 |
| ES2532357T3 (es) | 2015-03-26 |
| US8685977B2 (en) | 2014-04-01 |
| EP2593427A1 (en) | 2013-05-22 |
| EP2593427B1 (en) | 2014-12-24 |
| JP2013536165A (ja) | 2013-09-19 |
| TW201216956A (en) | 2012-05-01 |
| WO2012007883A1 (en) | 2012-01-19 |
| UY33500A (es) | 2012-02-29 |
| CA2804877A1 (en) | 2012-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082152A1 (es) | Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7 | |
| AR082153A1 (es) | N-sulfonilbenzamidas utiles como inhibidor del canal de sodio | |
| AR082201A1 (es) | Bencenosulfonamidas utiles como inhibidores del canal de sodio | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR087348A1 (es) | Indazoles, composiciones farmaceuticas que comprenden tales compuestos y su uso como medicamentos | |
| AR064389A1 (es) | Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen. | |
| AR058557A1 (es) | Derivados de pirimidina, procesos de preparacion, y composiciones farmaceuticas que los comprenden | |
| AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
| AR049300A1 (es) | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos | |
| AR090548A1 (es) | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k | |
| ES2626555T3 (es) | Pyridone amides como moduladores de canales de sodio | |
| NZ610312A (en) | 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR048939A1 (es) | Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios. | |
| AR072171A1 (es) | Derivados de nicotinamida, composicion farmaceutica que los comprende y su uso en combinaciones y en la preparacion de un medicamento para el tratamiento del asma. | |
| AR040700A1 (es) | Derivados de pirimidilsulfonamida como moduladores de receptores de quimioquinas | |
| AR088320A1 (es) | Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt | |
| BRPI0519287A2 (pt) | derivados de amida | |
| AR092749A1 (es) | Compuestos farmaceuticos | |
| AR048834A1 (es) | Compuestos derivados de piperidina o tropano; metodos para su preparacion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por quimioquinas (ccr5) | |
| AR096727A1 (es) | Derivados terapéuticamente activos de estratrien-tiazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |